Cite
HARVARD Citation
Baba, K. et al. (n.d.). 521PA randomized, phase II study comparing irinotecan versus amrubicin as maintenance therapy after first-line induction therapy for extensive disease small cell lung cancer (HOT1401/NJLCG1401). Annals of oncology. p. . [Online].